40.00
-0.25
(-0.62%)
May 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 40.00 - 41.00 |
| 52 week | 34.15 - 72.00 |
| Open | 40.25 |
| Vol / Avg. | 645,733.00/251,302.00 |
| Mkt cap | 32.61M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.05* |
| Shares | 81.53M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
May 23, 2013
ImmuPharma PLC Annual General Meeting
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -37.36% | -31.01% |
| Return on average equity | -43.92% | -36.74% |
| Employees | 7 | - |
| Carbon Disclosure Rating | - | - |
Address
50 Broadway, Westminster
LONDON, ENG SW1H 0RG
United Kingdom - Map
+44-20-71524080 (Phone)
+44-20-71524001 (Fax)
LONDON, ENG SW1H 0RG
United Kingdom - Map
+44-20-71524080 (Phone)
+44-20-71524001 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
ImmuPharma plc is a drug discovery and development company. The Company focuses on developing drugs, based on peptide therapeutics, to treat medical conditions such as autoimmune diseases. The Company has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). As of December 31, 2011, the Company had five drug candidates, such as Lupuzor to treat lupus; IPP-204106, to treat cancer; IPP-201007 to treat inflammation/allergic conditions, such as asthma and rheumatoid arthritis; IPP-102199 to treat moderate to severe pain, such as cancer and postoperative pain, and IPP-203101to treat severe resistant hospital-acquired infections, such as methicillin-resistant staphylococcus aureus (MRSA). As of March 27, 2012, Lupuzor received approval from the Food and Drug Administration to start a Phase III trial.
Officers and directors
| Richard Leonard Warr | Chairman of the Board | |
| Robert Henri Zimmer M.D., Ph.D. | President, Chief Scientific Officer, Director | |
| Dimitri F. Dimitriou | Chief Executive Officer, Director | |
| Tracy Weimar | Vice President - Operations and Finance, Company Secretary | |
| Ajay Agrawal | Non-Executive Independent Director | |
| Franco Di Muzio | Senior Non-Executive Independent Director |